Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs

Bioconjugate Chemistry

Volumn 20, Issue 2, 2009, Pages 390-396

  Ajaj, Khalid Abu ^a   Biniossek, Martin L ^b   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CARBOXYL GROUP; CATHEPSIN B; CYSTEINE; DOXORUBICIN; MALEIMIDE; PACLITAXEL; PRODRUG; THIOL GROUP;

ARTICLE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE; PROTEIN BINDING;

EID: 62549144354     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800429q     Document Type: Article

References (30)

1. Kratz, F., Abu Ajaj, K., and Warnecke, A. (2007) Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Invest. Drugs 16, 1037-1058.
2. Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3, 20-53.
3. King, H. D., Dubowchik, G. M., Mastalerz, H., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., and Trail, P. A. (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 45, 4336-4343.
4. Sugahara, S., Kajiki, M., Kuriyama, H., and Kobayashi, T. R. (2002) Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol Pharm. Bull. 25, 632-641.
5. Kratz, F., Warnecke, A., Schmid, B., Chung, D. E., and Gitzel, M. (2006) Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. 13, 763-771.
6. Akutsu, M., Kano, Y., Tsunoda, S., Suzuki, K., Yazawa, Y., and Miura, Y. (1995) Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur. J. Cancer 31A, 2341-2346.
7. Koechli, O. R., Sevin, B. U., Perras, J. P., Chou, T. C., Angioli, R., Steren, A., Untch, M., and Averette, H. E. (1993) Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res. Treat. 28, 21-27.
8. Amato, R. J., and Sarao, H. (2006) A phase I study of paclitaxel/ doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin. Genitourin Cancer 4, 281-286.
9. Zielinski, C. C. (2003) Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Williston Park) 17, 36-40.
10. Piccart-Gebhart, M. J., Burzykowski, T., Buyse, M., Sledge, G., Carmichael, J., Luck, H. J., Mackey, J. R., Nabholtz, J. M., Paridaens, R., Biganzoli, L., Jassem, J., Bontenbal, M., Bonneterre, J., Chan, S., Basaran, G. A., and Therasse, P. (2008) Taxanes alone or in combination with anthracyclines as firstline therapy of patients with metastatic breast cancer. J. Clin. Oncol. 26, 1980-1986.
11. Passardi, A., Massa, I., Zoli, W., Gianni, L., Milandri, C., Zumaglini, F., Nanni, O., Maltoni, R., Frassineti, G. L., and Amadori, D. (2006) Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer 6, 76.
12. Shimada, M., Kigawa, J., Terakawa, N., Yoshizaki, A., Shoji, T., Suzuki, M., Hatae, M., Tsuda, H., Ohwada, M., and Sugiyama, T. (2007) Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer. Int. J. Gynecol Cancer 17, 210-214.
13. Rodrigues, P. C. A., Scheuermann, K., Stockmar, C., Maier, G., Fiebig, H. H., Unger, C., Mülhaupt, R., and Kratz, F. (2003) Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 13, 355-360.
14. Carl, P. L., Chakravarty, P. K., and Katzenellenbogen, J. A. (1981) A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479-480.
15. Schmid, B., Chung, D. E., Warnecke, A., Fichtner, I., and Kratz, F. (2007) Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjugate Chem. 18, 702-716.
16. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 13, 855-869.
17. Kratz, F., Mueller-Driver, R., Hofmann, I., Drevs, J., and Unger, C. (2000) A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 43, 1253-1256.
18. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderung, C., Folkers, G., Fichtner, I., and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 45, 5523-5533.
19. Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M., Badary, O. A., Unger, C., Fichtner, I., and Kratz, F. (2003) A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63, 4062-4066.
20. Kratz, F., and Beyer, U. (1998) Serum proteins as drug carriers of anticancer agents: a review. Drug Delivery 5, 281-299.
21. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65, 271-284.
22. Kratz, F. (2007) DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 16, 855-66.
23. Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C., and Drevs, J. (2005) Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch. Pharm. (Weinheim) 338, 462-412.
24. Chung, D. E., and Kratz, F. (2006) Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16, 5157-5163.
25. Graeser, R., Chung, D. E., Esser, N., Moor, S., Schachtele, C., Unger, C., and Kratz, F. (2008) Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 122, 1145-1154.
26. Fiehn, C., Kratz, F., Sass, G., Muller-Ladner, U., and Neumann, E. (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann. Rheum. Dis. 67, 1188-1191.
27. Warnecke, A., Fichtner, I., Sass, G., and Kratz, F. (2007) Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch. Pharm. (Weinheim) 340, 389-395.
28. Kadereit, D., Deck, P., Heinemann, I., and Waldmann, H. (2001) Acid-labile protecting groups for the synthesis of lipidated peptides. Chem. Eur. J. 7, 1184-1193.
29. Dubowchik, G. M., and Radia, S. (1997) Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles. Tetrahedron Lett. 38, 5257-5260.
30. Abu Ajaj, K., and Kratz, F. (2009) Development of dual-acting prodrugs for circumventing multidrug resistance in breast cancer. Bioorg. Med. Chem. Lett., online, DOI: 10.1016/j.bmcl.2008.11.063.